US · Healthcare · Diagnostics & Research
EPS came in at -2.21 against a street estimate of -2.78 — a beat of 20.5%.
Analysts rate GRAIL, LLC a buy (5 buy, 5 hold, 0 sell out of 10) with an average price target of $132.56.
CONFIDENT GRAIL posted 26% revenue growth to $44.7M on 35% volume growth. Galleri detected 6.5× more cancers vs. standard care. FDA AdCom expected fall 2026; approval anticipated early 2027. Samsung $110M investment backs Asian expansion. Q2 2026 U.S. driving volume; NHS organizational changes creating near-term uncertainty but clinician enthusiasm remains high. Samsung partnership to drive Asia expansion starting South Korea. Analysts pressed on AdCom timing and specificity of FDA communication; management reaffirmed expectation but no new public details. Pricing pressure and competitive noise addressed via rigorous data differentiation and sales follow-up. Medicare NCD timing left speculative. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Farallon Capital Management, L.L.C. | 9.32% |
| Baker Bros Advisors LP | 9.02% |
| BlackRock Inc | 8.01% |
| Fort Hoosac Management, LLC | 6.95% |
| State Street Corp | 5.34% |
| PRIMECAP Management Company | 4.88% |
| Sessa Capital, L.P | 4.56% |
| Deep Track Capital, LP | 4.11% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $37.535 million, up from $36.194 million in the third quarter of 2025. • Nine-month 2026 revenue w | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $37.5 million, up 4% year over year; Galleri test revenue was $37.3 million, up 14%. • Q3 Galleri test | 2026-11-04 |
| Quarterly report · Q2 2026 GRAIL, INC. - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Securities Position: $55.6 million cash + $806.0 mill | 2026-08-06 |
| Results announced · Q3 2026 GRAIL Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $44.7 million, up 26% year-over-year • Q2 2026 Galleri Screening R | 2026-08-05 |
| Shareholder vote results · Q2 2026 GRAIL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 18, 2026 • 35,076,394 shares represented (81.7% of 42,916,593 total share | 2026-06-22 |
| Board / officer change · Q2 2026 GRAIL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Dr. Joshua Ofman appointed as Chief Executive Officer effective June 1, 2026 • Annual base salary | 2026-06-01 |
| Quarterly report · Q1 2026 GRAIL, Inc. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $69.3 million in cash and cash equivalents; $753.8 million in short-term market | 2026-05-07 |
| Results announced · Q2 2026 GRAIL Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $40.8 million, up 28% year-over-year • Galleri screening revenue: $39.8 mi | 2026-05-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GRAIL, LLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.